Concept
Genetic engineering techniques
Personnes associées (16)
Melanie Blokesch
Melanie Blokesch holds a PhD degree from the Ludwig-Maximilians-Universität in Munich, Germany. After a postdoctoral stay at Stanford University (USA; Department of Microbiology and Immunology) she joined EPFL as a tenure-track Assistant Professor in 2009 and was promoted to Associate Professor (tenured) in 2016. In 2018, Melanie Blokesch was nominated as new member of the the Swiss National Science Foundation (SNSF) National Research Council (starting date: April 2019). Melanie Blokesch is also an elected member of the European Academy of Microbiology (EAM; since 2018) and the European Molecular Biology Organization (EMBO; since 2019). Among other awards and grants, Melanie Blokesch has been honored with the Prize for Junior Scientists of the German National Academy of Sciences Leopoldina in 2005, an ERC Starting Grant in 2012, the EPFL teaching award "Polysphère" for best teacher in the School of Life Sciences (academic year 2014-2015), the Research Award by the Association for General and Applied Microbiology (VAAM; Germany) in 2015, and an ERC Consolidator Grant in 2016. In 2017, Melanie Blokesch was awarded a Howard Hughes Medical Institute (HHMI) International Research Scholarship.
Florian Maria Wurm
Florian Wurm received his academic training as a Biologist and Molecular Geneticist at the University of Giessen. He joined the Hoechst AG (Behringwerke) in Marburg as head of a laboratory in Virology. Working with immortalized mammalian cells for the establishment of production processes for alpha-interferons provided the first opportunity to combine basic research with medical application. In 1984 he joined Harvard Medical School in Boston as a Research Fellow in Molecular Biology. 1986 he took an offer from Genentech Inc. in San Francisco to work in Process Sciences on the development of large scale manufacturing processes for recombinant proteins. There he has held a number of leading positions and has acquired intimate knowledge in the generation of protein pharmaceuticals in mammalian cells in bioreactors (a number of which are now marketed products). In 1995 he joined the EPFL as a Professor for Biotechnology. Wurm has published more than 250 scientific papers and holds more than 20 patents/patent-applications. His H-index stands at 60 in 2021. He was Chairman (2005-2009) and is member of the Executive Board of the European Society of Animal Cell Technology (ESACT). He serves as a consultant to the pharmaceutical Biotech Industry, mainly in the fields of animal cell technology for recombinant protein production and in regulatory affairs. He works as a scientific reviewer and editior/asscciate editor for a number of international journals in the Biotech field. F.M. Wurm teaches classes to pre- and postgraduate students in the fields of Molecular and Cellular Biotechnology.
He was founder and Chief Scientific Officer of ExcellGene SA, a 2001 established company in Monthey, Switzerland. He took the position of President and CEO of ExcellGene in 2015. He retired from the CEO position in 2017 and continues to be President and Chief Scientific Officer of ExcellGene.
In 2008 Dr. Wurm was appointed Visiting Professor for Biotechnology at Jinan University in Guangzhou, China. He retired from his position at the EPFL in 2015. His laboratory is closed. With his team at ExcellGene and in collaboration with Dr. Paco Pino, Director of R&D, he continues to explore manufacturing sciences with animal cells in bioreactors.
Vassily Hatzimanikatis
Dr. Vassily Hatzimanikatis is currently Associate Professor of Chemical Engineering and Bioengineering at Ecole Polytechnique Federale de Lausanne (EPFL), in Lausanne, Switzerland. Vassily received a PhD and an MS in Chemical Engineering from the California Institute of Technology, and his Diploma in Chemical Engineering from the University of Patras, in Greece. After the completion of his doctoral studies, he held a research group leader position at the Swiss Federal Institute of Technology in Zurich (ETHZ), Switzerland. Prior to joining EPFL, Vassily worked for three years in DuPont, Cargill, and Cargill Dow, and he has been assistant professor at Northwestern University, at Illinois, USA.
Vassilys research interests are in the areas of computational systems biology, biotechnology, and complexity. He is associate editor of the journals Biotechnology & Bioengineering, Metabolic Engineering and Integrative Biology, and he serves on the editorial advisory board of the journals Bioprocess and Biosystems Engineering, Journal of Chemical Technology and Biotechnology, and Industrial Biotechnology. He has written over 70 technical publications and he is co-inventor in three patents and patent applications.
Vassily is a fellow of the American Institute for Medical and Biological Engineering (2010), he was a DuPont Young Professor (2001-2004), and he has also received the Jay Bailey Young Investigator Award in Metabolic Engineering (2000), and the ACS Elmar Gaden Award (2011).
Didier Trono
Après des études de médecine à l’Université de Genève et une formation clinique en pathologie, médecine interne et maladies infectieuses à Genève et au Massachusetts General Hospital de Boston, Didier Trono s’engage dans une carrière scientifique au Whitehead Institute du MIT. En 1990, il est recruté par le Salk Institute de San Diego pour lancer un centre de recherche sur le SIDA. Il rentre en Europe sept ans plus tard, avant de prendre en 2004 les rênes de la toute nouvelle faculté des Sciences de la Vie de l’EPFL, dont il orchestre le développement et qu’il dirige jusqu’en 2012. Il participe aujourd’hui activement à la coordination des efforts de la Suisse en vue de l’intégration des nouvelles technologies dans le domaine de la médecine de précision et de la santé personnalisée.
Patrick Aebischer
Patrick Aebischer a achevé une formation en Médecine (1980) et en Neurosciences (1983) aux Universités de Genève et de Fribourg en Suisse.
De 1984 à 1992, Patrick Aebischer a travaillé à Brown University (USA) au sein du Département des Neurosciences et au Département des Biomatériaux et des Organes Artificiels en tant que Professeur assistant, puis Professeur associé.
En 1992, Patrick Aebischer a été nommé Professeur de la Division Autonome de Recherche Chirurgicale et du Centre de Thérapie Génique (DARC) au Centre Hospitalier Universitaire Vaudois (CHUV) à Lausanne.
En 1999, Le Conseil Fédéral a nommé Patrick Aebischer en tant que Président de l'Ecole Polytechnique Fédérale de Lausanne (EPFL). Il a pris ses fonctions à la Présidence de lEPFL en mars 2000, position qu'il a occupée jusqu'au 31 décembre 2016.
Patrick Aebischer est membre de maintes sociétés professionnelles, tant en Europe quaux Etats-Unis.
Patrick Aebischer a fondé trois start-up de biotechnologies. Il siège au conseil d'administration de Lonza, de Logitech et de Nestlé. Il préside également l'advisory board du Novartis Venture Fund. Patrick Aebischer est membre du conseil de fondation du Festival de Jazz de Montreux, du Festival de Verbier et de la Fondation Jacobs.
Les recherches quil poursuit actuellement dans son laboratoire se concentrent sur le développement d'approches de thérapie cellulaire et de transfert génique pour le traitement des maladies neurodégénératives.
Carl Petersen
Carl Petersen studied physics as a bachelor student in Oxford (1989-1992). During his PhD studies under the supervision of Prof. Sir Michael Berridge in Cambridge (1992-1996), he investigated cellular and molecular mechanisms of calcium signalling. In his first postdoctoral period (1996-1998), he joined the laboratory of Prof. Roger Nicoll at the University of California San Francisco (UCSF) to investigate synaptic transmission and plasticity in the hippocampus. During a second postdoctoral period, in the laboratory of Prof. Bert Sakmann at the Max Planck Institute for Medical Research in Heidelberg (1999-2003), he began working on the primary somatosensory barrel cortex, investigating cortical circuits and sensory processing. Carl Petersen joined the Brain Mind Institute of the Faculty of Life Sciences at the Ecole Polytechnique Federale de Lausanne (EPFL) in 2003, setting up the Laboratory of Sensory Processing to investigate the functional operation of neuronal circuits in awake mice during quantified behavior. In 2019, Carl Petersen became the Director of the EPFL Brain Mind Institute, with the goal to promote quantitative multidisciplinary research into neural structure, function, dysfunction, computation and therapy through technological advances.
Bruno Emanuel Ferreira De Sousa Correia
Throughout my PhD and postdoctoral studies I was trained in world-renowned laboratories and institutions in the United States of America (University of Washington and The Scripps Research Institute). Very early in my scientific career I found out my fascination about protein structure and function. My PhD studies evolved in the direction of immunogen design and vaccine engineering which sparked my interest in the many needs and opportunities in vaccinology and translational research. My efforts resulted in an enlightening piece of work where for the first time, computationally designed immunogens elicited potent neutralizing antibodies. During my postdoctoral studies I joined a chemical biology laboratory at the Scripps Research Institute. In this stage I developed novel chemoproteomics methods for the identification of protein-small molecule interaction sites in complex proteomes. In March 2015, I joined the École Polytechnique Fédérale de Lausanne (EPFL) – Switzerland as a tenure track assistant professor. The focus of my research group is to develop computational tools for protein design with particular emphasis in applying these strategies to immunoengineering (e.g. vaccine and cancer immunotherapy). The activities in my laboratory focus on computational design methods development and experimental characterization of the designed proteins. Our laboratory has been awarded with 2 prestigious research grants from the European Research Council. Lastly, I have been awarded the prize for best teacher of Life sciences in 2019.
Denis Duboule
Denis Duboule est né en 1955. De Nationalités Suisse et Française, il étudie la biologie à lUniversité de Genève où il reçoit un PhD dans le domaine de lembryologie des mammifères en 1984. Il passe ensuite 10 ans à létranger, dabord comme post-doc et group leader à la faculté de Médecine de Strasbourg (CNRS), puis au Laboratoire Européen de Biologie Moléculaire, à Heidelberg (Allemagne). En 1993, il est nommé Professeur ordinaire à lUniversité de Genève, où il dirige le département de Génétique et Evolution depuis 1997. En 2001 il prend la direction du pôle dexcellence NCCR aux Frontières de la Génétique et celle de la division médecine-Biologie du FNS en 2012. En 2006, il est nommé Professeur ordinaire à lEPFL, Lausanne, où il dirige le laboratoire de Génomique du Développement (UpDUB).
Ses activités de recherche sexercent dans le domaine de lembryologie, de la génétique et de la génomique du développement des mammifères, dans le contexte général de lEvolution des structures et des organes. En particulier, son laboratoire a été associé à de nombreuses recherches dans le domaine de lanalyse structurelle et fonctionnelle des gènes architectes (Hox) et de leur régulation transcriptionnelle pendant le développement précoce. Denis Duboule est également actif dans le domaine de la communication de la science. Il est membre de lAcademia Europea ainsi que dautres académies. Il est également membre de lInstitut de France (Académie des Sciences), de la Société Royale (UK) et de lAcadémie des Sciences Américaine (NAS). Il a reçu plusieurs prix et distinction, notamment le Prix Marcel Benoist, le Prix Louis-Jeantet de Médecine en 1998 et le Prix international de lINSERM en 2010. Voir également https://fr.wikipedia.org/wiki/Denis_Duboule.